| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| BELVIN MARCIA | SVP, Chief Scientific Officer | C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO | /s/ Christopher Ogden, as Attorney-in-Fact for Marcia Belvin | 04 Feb 2026 | 0001970752 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CTMX | Common Stock | Award | $0 | +60,000 | +22% | $0.000000 | 332,252 | 02 Feb 2026 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CTMX | Stock Option (Right to Buy) | Award | $0 | +250,000 | $0.000000 | 250,000 | 02 Feb 2026 | Common Stock | 250,000 | $6.09 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date. |
| F2 | Includes 218,958 RSUs. |
| F3 | 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |